MTCR News and Press, Metacrine Inc. From 04/15/21

Shares of Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.72. So far today approximately 264,000 shares have been exchanged, as compared to an average 30-day volume of 79,000 shares. Potential upside of 9.3% exists for Metacrine Inc., based on a current level of $4.7...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded today at $4.78, breaking its 52-week low. Approximately 264,000 shares have changed hands today, as compared to an average 30-day volume of 79,000 shares. In the past 52 weeks, shares of Metacrine Inc. have traded between the current low of $...

Metacrine Inc. (NASDAQ:MTCR) traded at a new 52-week low today of $4.75. Approximately 264,000 shares have changed hands today, as compared to an average 30-day volume of 79,000 shares. Metacrine Inc. (NASDAQ:MTCR) has potential upside of 7.1% based on a current price of $4.82 and analys...

Shares of Metacrine Inc. (NASDAQ:MTCR) traded today at $5.23, breaking its 52-week low. So far today approximately 264,000 shares have been exchanged, as compared to an average 30-day volume of 45,000 shares. In the past 52 weeks, Metacrine Inc. share prices are bracketed by a current lo...

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced the appointment of Julia C. Owens, Ph.D. to the Company’s...

Metacrine (MTCR): Q4 net loss of $10.82MCash, cash equivalents and short-term investments of $96.2MPress Release For further details see: Metacrine reports Q4 results

The IPO market starts to pick back up with eight IPOs scheduled to raise $2.2 billion in the week ahead. Street research is expected for one company on Sunday, 3/14. Lock-up periods will be expiring for 15 companies. For further details see: U.S. IPO Week Ahead: The Spri...

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that final results from the company&...

SAN DIEGO, March 11, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that management will host a conferen...

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases, today announced that the first patient has been trea...